Anthony G. Letai, accompanied by his wife Jean, was sworn in by HHS Secretary Kennedy as the 18th NCI Director on Sept. 29.Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute, has been officially named the 18th director of the National Cancer Institute.
On Oct. 1, for the first time in six years, the U.S. government shut down after Congress was unable to reach a deal to fund federal agencies for Fiscal Year 2026.
President Trump has signed an executive order to use artificial intelligence to accelerate research in pediatric cancers.
The University of Cincinnati Cancer Center’s Joan Garrett has received a two-year, $162,000 NCI grant to study a new combination approach to treat KRAS-mutated colorectal cancers.
With little fanfare, Anthony Letai, a highly respected physician-scientist, was sworn in as the 18th director of the National Cancer Institute on Sept. 29. Then, two days later, on Oct. 1, the government shut down.
There is a silent crisis in cancer research that underpins nearly all aspects of the work we do to combat this disease.
Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute whose research is focused on apoptosis and functional diagnostics, has been tapped by the Trump administration to become the 18th director of the National Cancer Institute.
With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.
Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.
NCI has released the names of the members of the newly formed ad hoc Working Group on Extramural Research Concepts and Programs. The group will perform the peer review functions of the now-defunct Board of Scientific Advisors.
